Targeted intracellular accumulation of macrophage migration inhibitory factor in the reperfused heart mediates cardioprotectionFinancial support: This work was supported by the Deutsche Forschungsgemeinschaft (DFG) grants Be1977/4–2 (TP1 of DFG-FOR809) and GRK1508/1 (project P13) to J.B., Ra969/6–1 to T.R. and J.B. T.R. is a Heisenberg professor funded by the DFG (Ra969/7–2). PL is funded by the Medical Faculty of the University of Düsseldorf. There are no relationships with industry.
27 May 2015
Accepted after minor revision: 09 July 2015
22 November 2017 (online)
S-nitrosation of macrophage migration inhibitory factor (MIF) has been shown to be cytoprotective in myocardial ischaemia/reperfusion (I/R) injury. Since the exact mechanism of action is unknown, we here characterise the cardioprotective effects of targeted intracellular accumulation of MIF in myocardial I/R injury. We used different in vivo, ex vivo and in vitro models of myocardial I/R and hypoxia/reoxyge-nation (H/R) injury to determine MIF levels by immunoblots and ELISA in different phases of reperfusion and reoxygenation, respectively. We discovered a rapid decrease of cardiac MIF that was specific to the early phase of reperfusion. Posttranslational modification of MIF via S-nitrosation – proofed by a modified version of the Biotin Switch Assay – prevented this rapid decrease, leading to a targeted intracellular accumulation of MIF in the early phase of reperfusion. Intracellular MIF accumulation preserved the intracellular ability of MIF to reduce oxidative stress as shown by hydrogen peroxide and aconitase activity measurements. Infarct size measurements by TTC staining showed an overall enhanced cardioprotective effect of this protein by reduction of reperfusion injury. In summary, we have unravelled a novel mechanism of MIF-mediated cardioprotection. Targeted intra-cellular accumulation of MIF by S-nitrosation may offer a novel therapeutic approach in the treatment of myocardial I/R-injury.
- 1 Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.
- 2 Hearse DJ, Humphrey SM, Nayler WG. et al. Ultrastructural damage associated with reoxygenation of the anoxic myocardium. J Mol Cell Cardiol 1975; 07: 315-324.
- 3 Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. J Biol Chem 1988; 263: 1353-1357.
- 4 Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998; 38: 291-300.
- 5 Holmgren A, Johansson C, Berndt C. et al. Thiol redox control via thioredoxin and glutaredoxin systems. Biochem Soc Trans 2005; 33: 1375-1377.
- 6 Koga K, Kenessey A, Powell SR. et al. Macrophage migration inhibitory factor provides cardioprotection during ischaemia/reperfusion by reducing oxidative stress. Antioxid Redox Signal 2011; 14: 1191-1202.
- 7 Luedike P, Hendgen-Cotta UB, Sobierajski J. et al. Cardioprotection through S-nitros(yl)ation of macrophage migration inhibitory factor. Circulation 2012; 125: 1880-1889.
- 8 Rassaf T, Weber C, Bernhagen J. Macrophage migration inhibitory factor in myocardial ischaemia/reperfusion injury. Cardiovasc Res 2014; 102: 321-328.
- 9 Sun HW, Bernhagen J, Bucala R. et al. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1996; 93: 5191-5196.
- 10 Kleemann R, Kapurniotu A, Frank RW. et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 1998; 280: 85-102.
- 11 Miller EJ, Li J, Leng L. et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008; 451: 578-582.
- 12 Fingerle-Rowson G, Petrenko O, Metz CN. et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci USA 2003; 100: 9354-93559.
- 13 Hendgen-Cotta UB, Merx MW, Shiva S. et al. Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischaemia-reper-fusion injury. Proc Natl Acad Sci USA 2008; 105: 10256-10261.
- 14 Totzeck M, Hendgen-Cotta UB, Luedike P. et al. Nitrite regulates hypoxic vasodilation via myoglobin-dependent nitric oxide generation. Circulation 2012; 126: 325-334.
- 15 Sobierajski J, Hendgen-Cotta UB, Luedike P. et al. Assessment of macrophage migration inhibitory factor in humans: protocol for accurate and reproducible levels. Free Radic Biol Med 2013; 63: 236-242.
- 16 Rammos C, Hendgen-Cotta UB, Sobierajski J. et al. Macrophage migration inhibitory factor is associated with vascular dysfunction in patients with end-stage renal disease. Int J Cardiol 2013; 168: 5249-5256.
- 17 Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. Sciences STKE 2001; 2001: pl1.
- 18 Rassaf T, Totzeck M, Hendgen-Cotta UB. et al. Circulating nitrite contributes to cardioprotection by remote ischaemic preconditioning. Circ Res 2014; 114: 1601-1610.
- 19 Rammos C, Hendgen-Cotta UB, Pohl J. et al. Modulation of circulating macrophage migration inhibitory factor in the elderly. BioMed Res Intern 2014; 2014: 582586.
- 20 Claycomb WC, Lanson Jr. NA, Stallworth BS. et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 1998; 95: 2979-2984.
- 21 Horstkotte J, Perisic T, Schneider M. et al. Mitochondrial thioredoxin reductase is essential for early postischaemic myocardial protection. Circulation 2011; 124: 2892-2902.
- 22 Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nature Protocols 2008; 03: 1125-1131.
- 23 Kleemann R, Hausser A, Geiger G. et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000; 408: 211-216.
- 24 Lue H, Thiele M, Franz J. et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007; 26: 5046-5059.
- 25 Burger-Kentischer A, Goebel H, Seiler R. et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002; 105: 1561-1566.
- 26 Yu CM, Lai KW, Chen YX. et al. Expression of macrophage migration inhibitory factor in acute ischaemic myocardial injury. J Histochem Cytochem 2003; 51: 625-631.
- 27 Calandra T, Bernhagen J, Mitchell RA. et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179: 1895-1902.
- 28 Tubergen DG, Feldman JD, Pollock EM. et al. Production of macrophage migration inhibition factor by continuous cell lines. J Exp Med 1972; 135: 255-266.
- 29 Takahashi M, Nishihira J, Shimpo M. et al. Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc Res 2001; 52: 438-445.
- 30 Fukuzawa J, Nishihira J, Hasebe N. et al. Contribution of macrophage migration inhibitory factor to extracellular signal-regulated kinase activation by oxidative stress in cardiomyocytes. J Biol Chem 2002; 277: 24889-24895.
- 31 Lue H, Kapurniotu A, Fingerle-Rowson G. et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 2006; 18: 688-703.
- 32 Rendon BE, Willer SS, Zundel W. et al. Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol 2009; 86: 180-185.
- 33 Xu L, Eu JP, Meissner G. et al. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 1998; 279: 234-237.
- 34 Kleemann R, Mischke R, Kapurniotu A. et al. Specific reduction of insulin disulfides by macrophage migration inhibitory factor (MIF) with glutathione and dihydrolipoamide: potential role in cellular redox processes. FEBS Lett 1998; 430: 191-196.
- 35 Lima B, Forrester MT, Hess DT. et al. S-nitrosylation in cardiovascular signalling. Circ Res 2010; 106: 633-646.
- 36 Lopaschuk GD. AMP-activated protein kinase control of energy metabolism in the ischaemic heart. Int J Obes 2008; 32 (Suppl. 04) S29-35.
- 37 Young LH, Li J, Baron SJ. et al. AMP-activated protein kinase: a key stress signalling pathway in the heart. Trends Cardiovasc Med 2005; 15: 110-118.
- 38 Kim AS, Miller EJ, Young LH. AMP-activated protein kinase: a core signalling pathway in the heart. Acta Physiol 2009; 196: 37-53.